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Preliminary and Short Report
THE ANTI-SEBORRHEIC QUALITIES OF ZINC PYRITHIONE
(ZINC PYRIDINE-2-THIOL-1-OXIDE) IN
A CREAM VEHICLE
I. A PRELIMINARY REPORT*
EARLE W. BEAUER, M.D., DONALD L. OPDYKE, PH.D. AND
CLYDE M. BURNETT
Keratolytic or desquamating agents have been
employed as anti-seborrheic medicaments. Some
thiols are among the agents cited (1) as possessing
keratin reducing abilities. A totally new compound,
whose possible use in pharmaceutical preparations
(2) was suggested in 1957, was investigated to
determine its possible effectiveness as an anti-
seborrheic remedy.
GE5CRIPTION OF ACTIVE AGENT
Zinc pyrithione (ZPT), also known as zinc pyri-
dine-2-thiol-1-oxide has the empirical formula
CHIIIN2O2SIZn and the structural formula:
O>KS
zinc pyridine-2-thiol-1-oxide
Its possible use in pharmaceutical preparations
was suggested as early as 1957 (2).
TOXICOLOGY
Toxicologic data on this active agent became
available in 1958; and an extensive review has re-
cently been published (3) evaluating the safety of
the compound in a 2% concentration in a shampoo
vehicle.
Similarly, toxicologic data is presented with a
ZPT concentration of 0.5% in a cream vehicle to
be used for repeated application to the scalp
(Table I).
Zinc pyrithione has demonstrable toxicity on re-
peated ingestion, but apparently insufficient
amounts, if any, penetrate intact or abraded skin
to produce any manifestations of toxicity. An acute
dermal toxicity with the 50% suspension as ob-
tained from the suppliert failed to elicit any re-
sponse at doses of 20 gm/kg of body weight or
10 gms of pure ZPT.
While, like several other antibacterial agents,
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t Olin, Inc., Organics Division, Speciality Chem-
ical Products, 100 McKee Road, P.O. Box 206,
Rochester, N. Y.
ZPT discolors and decomposes in the presence of
ultraviolet light, the degraded product does not
differ in cutaneous irritation or acute oral toxicity
from the original material.
Antimicrobiol Activity
In vitro tests in our laboratories against &ophy-
lococcus oureus and albus and Pityrosporum ovole,
revealed ZPT to be several hundred times more
effective than resorcinol, salicylic acid, sulfur and
related compounds.
Humon Potch Tests
Repeated insult closed-patch-tests with the 0.5%
concentration of ZPT in the cream vehicle on 100
human volunteers over a consecutive 20 week
period was followed by a final challenge after a 2
week rest interval. There was no evidence of ad-
verse reaction.
Clinicol Experience
The Cream vehicle containing 0.5% ZPT was
utilized as a hairdressing for daily gentle massage
to the scalp in patients with seborrheic dermatitis
(pityriasis capitis). Subjects from 11—80 years of
age with eruption of various degrees of severity
comprised the study carried out in two phases:
I—a simple clinical evaluation for effectiveness;
and Il—a double-blind evaluation against a posi-
tive controlt in patients from the private prac-
tices of 5 dermatologists in several geographic
areas. In all cases, the subjects were observed for at
least 2 weeks, while using mild shampoos, before
the treatment program was instituted.
Clinical response was gradual, with pronounced
improvement in signs and symptoms in a majority
t The control product consisted of the same
cream vehicle as the test product; however the
active agents dehydroacetate salt, para-chloro-
meta-xylenol and allantoin were substituted for the
ZPT. The control product, with established anti-
seborrheic qualities, has been marketed for 8 years.§ We are indebted to the following dermatolo-
gists for their cooperation in this clinical study:
Leonard D. Grayson, M.D., Quincy, Illinois; A. A.
Cuiducci, M.D., Warren, Ohio; D. E. Rackbarth,
M.D., Milwaukee, Wisconsin; C. Conrad Smith,
MD,. Augusta, Georgia.
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TABLE I
Summary of toxicology of ZPT 0.5% in a cream vehicle
* Food and Drug Research Laboratories, Inc., 58th Street and Maurice Avenue, Maspeth, 78, Queens,
N.Y.
No.of
subjects
85
Severity of disease
Severe
2
I
Moder-
ately I Moder- Mildate ISevere I
9 38 19
Slight
12
No. of
subjects
Results
Excellent Good Fair Poor Off Test
85 63 14 1 2 5
of patients appearing by the third week. Continued
use yielded progressive benefit which was main-
tained indefinitely (some cases observed for 3
years) on a reduced schedule of use. There were
no instances of adverse reactions.
SUMMARY AND CONCLUSION
A new compound, zinc pyrithione, 0.5% concen-
tration in a cream vehicle, has been demonstrated
to be very effective in the treatment of seborrheic
dermatitis (pityriasis capitis).
The possible usefulness of this remedy in the
treatment of other dermatologic conditions is be-
ing investigated.
TABLE III
Phase II: A double-blind evaluation
(against a positive control)
Active 200
Control 67
Severity of disease
Severe
Moder-
ately
Severe
Moder-
ate Mild Slight
8 29 81 63 4
7 10 25 17 2
Results
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Test Level Animal Where performed Result
LD5° 0.5% Fasted albino rat Revlon Research >30 g/kg
Center
Eye irritation 0.5% Albino rabbit Revlon Research
Center
Passes
test
Draize
20 day percutaneous lx, lOx use level Albino rabbit Food and Drug* Negative
on abraded skin Research Labs
90 day percutaneous lx, lOx, lOOx use Albino rabbit Food and Drug Negative
on intact skin level Research Labs
Acute dermal toxic- 20 g/kg (100 mg Albino rabbit Revlon Research Negative
ity ZPT) Center
TABLE II
Phase I: Simple clinical evaluation for
effectiveness
No. of subjects
No. of subjects
Active 200
Control 67
Excel-
lent
79
18
Good
51
11
Fair
21
8
Poor
34
24
Off Test
15
6
